- Home
- MIRA
as 11-14-2024 11:35am EST
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 17.1M | IPO Year: | 2023 |
| Target Price: | $14.00 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $6.40 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MIRA Pharmaceuticals Inc. (MIRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McNulty Brian Patrick | MIRA | 10% Owner | Aug 28 '24 | Sell | $1.96 | 200,000 | $392,000.00 | 2,540,270 |
Latest MIRA Pharmaceuticals Inc. News
MIRA Breaking Stock News: Dive into MIRA Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
2 days ago
MIRA Continues Solid Financial Management
GuruFocus.com
17 days ago
MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
Benzinga
18 days ago
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
ACCESSWIRE
18 days ago
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
Market Exclusive
18 days ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024
ACCESSWIRE
25 days ago
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Zacks Small Cap Research
25 days ago
MIRA Continues to Post Outstanding Test Results
MT Newswires
2 months ago
MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models
Compare MIRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRA MIRA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.